Testosterone therapy for women after menopause has one stronger evidence category: hypoactive sexual desire disorder, after a careful biopsychosocial assessment. Low desire can feel like a hormone problem, especially when hot flashes, sleep loss, vaginal dryness, mood changes, and body changes arrive together. Testosterone may be relevant for some women, but the evidence is narrower than most online ads suggest.
The global consensus statement on testosterone therapy for women names one evidence-based use: hypoactive sexual desire disorder, in women after menopause. [1] That is not the same as using testosterone for fatigue, weight loss, mood, memory, muscle gain, or anti-aging.
The Endocrine Society guideline also cautions against broad androgen therapy in women outside carefully selected sexual-dysfunction contexts. [4]
The trial signal is real but specific. A 2019 meta-analysis pooled 36 randomized trials with 8,480 women. It found improvements in several sexual-function outcomes in postmenopausal women, including 0.85 more satisfactory sexual events on average, while acne and hair growth were more likely and no benefit was shown for body composition, musculoskeletal outcomes, or cognitive measures. [2]
When might testosterone therapy help women after menopause?
For women, testosterone blood levels are hard to interpret. The consensus statement says no blood cutoff reliably separates women with sexual dysfunction from women without it. [1]
That does not mean labs are useless. They help set a baseline. They also reduce the risk of too-high dosing. But the diagnosis starts with the symptom pattern and distress: persistent low sexual desire that bothers the patient, after other causes have been considered.
Those other causes matter. Painful sex, vaginal dryness, relationship strain, depression, anxiety, selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor use, sleep loss, alcohol, trauma history, thyroid disease, untreated hot flashes, and caregiving overload can all reduce desire. Testosterone should not be used to skip that workup.
The symptom pattern matters
Female sexual symptoms are not one thing. Desire, cognitive arousal, genital arousal, orgasm, pain, relationship context, and distress can overlap, but they are clinically different enough that an intake should separate them. International Society for the Study of Women's Sexual Health nomenclature work emphasizes targeted clinical interview questions and biopsychosocial risk factors when assessing female sexual arousal and desire problems. [6]
| Pattern at intake | First question | Why it changes the plan |
|---|---|---|
| Low desire with distress | Is this persistent and unwanted after menopause? | This is the category where testosterone may be discussed if other causes are addressed. |
| Pain with sex or vaginal dryness | Is genitourinary syndrome of menopause or pelvic pain the main blocker? | Vaginal estrogen, moisturizers, pelvic care, or pain treatment may come before testosterone. |
| Low arousal but desire is present | Is the issue cognitive arousal, genital arousal, or both? | Arousal problems should not be collapsed into "low testosterone." |
| Mood, sleep, medication, or relationship stress | Is desire low because the context is medically or emotionally overloaded? | Treating the driver may be more useful than adding androgen therapy. |
| Hair loss, acne, or unwanted hair growth | Are androgen effects already part of the concern? | Baseline symptoms affect risk tolerance and monitoring. |
What benefit did trials show?
A 2019 review and meta-analysis included 36 randomized trials and 8,480 women. Testosterone improved several sexual-function outcomes, especially with non-oral products. The authors also found more androgen effects, such as acne and hair growth. Oral testosterone had worse lipid effects than non-oral routes. [2]
The practical view is moderate, not magical. Testosterone may increase desire and satisfying sexual events for selected women after menopause with hypoactive sexual desire disorder. It is not a broad guarantee of libido, energy, confidence, or body composition.
Why formulations and dose targets matter
The International Society for the Study of Women's Sexual Health clinical practice guideline sets standards for prescribing systemic testosterone for women with hypoactive sexual desire disorder. It covers patient selection, baseline testing, dosing, and follow-up monitoring. [3]
The core safety idea is to keep testosterone in the usual female range and avoid too-high exposure. That is why pellets, high-dose compounded products, and unclear dosing deserve extra caution. More testosterone is not the endpoint. Symptom improvement without androgen side effects is the endpoint.
That caution should not be flattened into a blanket anti-compounding rule. If a clinician considers a compounded testosterone product because no FDA-approved female testosterone product fits the case, the patient-specific reason, pharmacy source, exact strength, concentration, route, monitoring schedule, and stop rule need to be explicit. FDA's general compounding guidance recognizes patient-specific needs, while testosterone-specific guidance still requires physiologic dosing discipline. [7] [3]
Common monitoring questions include acne, facial hair growth, scalp hair thinning, voice changes, clitoral symptoms, mood changes, lipids when relevant, and benefit. Is the patient actually improving enough to justify continuing?
A 2025 position statement on androgen therapy in midlife and older women reached the same practical boundary: testosterone therapy for postmenopausal women should be limited to hypoactive sexual desire disorder confirmed through formal biopsychosocial evaluation, transdermal routes are preferred, and subcutaneous pellets plus compounded "bioidentical" testosterone are not recommended because of supraphysiologic dosing risk and insufficient evidence. [5]
| Monitoring point | What a careful plan specifies |
|---|---|
| Baseline diagnosis | hypoactive sexual desire disorder after biopsychosocial assessment, not low testosterone alone |
| Baseline labs | Total testosterone for safety context, with lipids and liver context when clinically relevant |
| Dose target | Physiologic female-range exposure, not an "optimized" high number |
| Early follow-up | Symptom benefit and androgen-excess signs such as acne, facial hair, scalp hair loss, voice change, and clitoral symptoms |
| Stop rule | Stop or reassess if there is no meaningful benefit, side effects appear, or levels rise above the intended range |
Decision table: when testosterone matches the evidence
| Decision point | Better fit | Poorer fit |
|---|---|---|
| Main symptom | Persistent low desire with distress after menopause. | Fatigue, weight, mood, brain fog, or anti-aging as the main goal. |
| Assessment | Pain, genitourinary syndrome of menopause, mood, sleep, medication, relationship, and medical factors reviewed. | A low lab value is treated as the diagnosis. |
| Product | Doseable route with monitoring and female-range exposure. | Pellet, high-dose, or unclear compounded exposure without a documented patient-specific reason. |
| Response target | Desire/distress improves without androgenic side effects. | Dose is increased because the number is not "optimized." |
| Stop rule | No meaningful benefit or side effects leads to reassessment. | Treatment continues indefinitely without a response check. |
What a careful treatment trial should look like
A testosterone discussion should produce a clear plan, not just a prescription. A careful plan names:
- The diagnosis being treated, usually hypoactive sexual desire disorder after a biopsychosocial assessment.
- The baseline testosterone result, used for safety context rather than diagnosis by itself.
- The product and dose, with a goal of staying in the usual female range.
- If the product is compounded, the patient-specific reason, pharmacy source, ingredients, strength, concentration, and dose-unit instructions.
- The symptom endpoint: desire, distress, satisfying sexual events, or another agreed measure.
- The stop rule if there is no meaningful benefit or side effects appear.
This is also where formulation risk belongs. The consensus and International Society for the Study of Women's Sexual Health guidance are much more comfortable with physiologic dosing than with supraphysiologic exposure. [1] [3] If a product cannot be dosed or monitored clearly, it does not fit the safety standard.
What testosterone should not be asked to treat
The evidence is not strong enough to use testosterone as a default treatment for midlife fatigue, brain fog, weight gain, depression, joint pain, or anti-aging. The global statement reports insufficient evidence for cognitive performance or delaying cognitive decline in women after menopause. It also does not support broad disease-prevention claims. [1]
This matters because "testosterone for women" is a high-intent category. It can also become unsafe if it imports male TRT positioning. The safer version must be narrower: women, menopause context, sexual desire distress, clinician assessment, careful dosing, and monitoring.
A better intake question
Instead of "Do I have low T?" the better question is:
Is low desire causing distress after menopause? Have the common non-testosterone causes been checked?
If yes, testosterone may be a clinician-supervised option. If no, the next step may be sleep treatment, vaginal estrogen or other vaginal and urinary care, medication review, mood care, relationship work, pain treatment, or menopause symptom control. The right answer depends on the pattern, not on one lab value.
If hair shedding or acne is part of the concern, the testosterone visit should connect with the menopause hair-loss review, not ignore it. If hot flashes and night sweats are the dominant problem, the hormone therapy review may be the better starting point.
Who may benefit and who should avoid rushing
Testosterone review may fit a postmenopausal woman with persistent low desire that causes distress after common contributors have been reviewed.
It is a poor fit when the main goal is energy, confidence, weight loss, mood, cognition, muscle gain, or anti-aging. It is also a poor fit when the plan skips pain with sex, vaginal dryness, relationship context, mood, sleep, medication effects, thyroid disease, anemia, or hot flashes.
Red flags include supraphysiologic dosing, unclear compounded dosing, pellets presented as routine, acne or unwanted hair growth, scalp hair loss, voice change, clitoral symptoms, abnormal lipids, liver disease complexity, or no stop rule.
What to ask a clinician
Ask:
- Do my symptoms meet hypoactive sexual desire disorder criteria after a biopsychosocial assessment?
- What non-testosterone causes of low desire should be addressed first?
- What product, dose, monitoring plan, and female-range target will be used?
- What side effects mean the dose is too high?
- What is the stop rule if desire and distress do not improve?
Bottom line
For women after menopause, testosterone has one stronger evidence category: carefully assessed hypoactive sexual desire disorder.
That category is clinically useful, but narrow. It should not be stretched into a general midlife optimization offer.
How the assessment helps
A structured assessment can organize low-desire distress, genitourinary syndrome of menopause or pain symptoms, sleep, mood, medicines, relationship context, hair or acne concerns, prior hormone use, and safety red flags so a clinician can decide whether hypoactive sexual desire disorder evaluation, vaginal care, medication review, testosterone monitoring, or another route fits. It is not a testosterone prescription by itself.
Related reading:
- Testosterone Monitoring for Women After Menopause.
- Testosterone Blood Test for Women.
- Testosterone Pellets for Women After Menopause.
- Testosterone Side Effects in Women.
References
[1] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[2] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[3] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Climacteric. 2021;24(6):533-550. doi:10.1080/13697137.2021.1891773 https://pubmed.ncbi.nlm.nih.gov/33792440/
[4] Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. doi:10.1210/jc.2014-2260 https://pubmed.ncbi.nlm.nih.gov/25279570/
[5] Pilnik S, Belardo A, Marchesan LB, et al. Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG). Climacteric. 2025;28(5):529-536. doi:10.1080/13697137.2025.2548805 https://pubmed.ncbi.nlm.nih.gov/40919649/
[6] Parish SJ, Meston CM, Althof SE, et al. Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part III. J Sex Med. 2019;16(3):452-462. doi:10.1016/j.jsxm.2019.01.010 https://pubmed.ncbi.nlm.nih.gov/30846116/
[7] FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers